Exchange Traded Concepts LLC Trims Position in Novo Nordisk A/S $NVO

Exchange Traded Concepts LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 20.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,234 shares of the company’s stock after selling 37,600 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Novo Nordisk A/S were worth $7,010,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Certuity LLC grew its stake in Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares in the last quarter. Oakworth Capital Inc. boosted its holdings in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the period. Werba Rubin Papier Wealth Management grew its stake in Novo Nordisk A/S by 6.0% in the fourth quarter. Werba Rubin Papier Wealth Management now owns 4,270 shares of the company’s stock worth $217,000 after purchasing an additional 241 shares in the last quarter. Finally, CoreCap Advisors LLC grew its stake in Novo Nordisk A/S by 4.7% in the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after purchasing an additional 242 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NVO. BMO Capital Markets reaffirmed a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Berenberg Bank set a $47.00 price objective on Novo Nordisk A/S in a report on Wednesday. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Four analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $46.75 on Friday. The firm has a 50 day moving average of $47.30 and a 200 day moving average of $44.50. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $208.74 billion, a price-to-earnings ratio of 11.43, a price-to-earnings-growth ratio of 4.23 and a beta of 0.76. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion for the quarter. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a dividend of $0.5786 per share. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 42.79%.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market will not be “winner-take-all,” arguing that patients’ differing preferences and demand for pills, injectables and other differentiated treatments should support multiple successful players. Reuters article
• Positive Sentiment: Novo’s oral Wegovy appears to be generating strong prescription momentum, offering a potential new growth channel and helping the company compete beyond its injectable portfolio. However, investors are watching whether that momentum can offset Lilly’s faster growth. Zacks article
• Positive Sentiment: Zacks Research upgraded NVO from “strong sell” to “hold,” indicating that the stock’s sharp decline and low earnings multiple may have reduced some downside risk.
• Neutral Sentiment: Novo defended its lawsuit challenging Eli Lilly’s weight-loss advertising, saying competition must be fair. The litigation could protect Novo’s marketing position, but it also highlights the intensity of the competitive battle. CNBC article
• Neutral Sentiment: Novo’s CEO continues to promote a long runway for obesity treatments, citing low overall adoption and potential healthcare-cost benefits. These are long-term opportunities rather than immediate earnings catalysts. Fox Business article
• Negative Sentiment: Eli Lilly’s growing share in both injectable and oral weight-loss drugs is the main concern. Analysts warn that Lilly’s momentum could widen the competitive gap and limit the upside investors had anticipated from the Wegovy pill. Yahoo Finance article
• Negative Sentiment: Berenberg downgraded Novo from “buy” to “hold,” citing expectations that the initial Wegovy-pill upside is already reflected in the stock and valuing the company closer to the broader European pharmaceutical sector.
• Negative Sentiment: Recent analysis also points to flat Wegovy sales, pricing pressure and pipeline setbacks as near-term risks, helping explain why NVO has decreased despite its strong margins and broader cardiometabolic pipeline. Zacks analysis

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.